Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).
FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies
Revisit the OncLive On Air Episodes From February 2024
BTK Inhibitor Selection for CLL/SLL Is Evolving in Community Settings
Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma